Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Current Deferred Revenue (2017 - 2020)

Aytu Biopharma has reported Current Deferred Revenue over the past 6 years, most recently at $475680.0 for Q4 2020.

  • Quarterly Current Deferred Revenue changed N/A to $475680.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $475680.0 through Dec 2020, changed N/A year-over-year, with the annual reading at $339336.0 for FY2020, N/A changed from the prior year.
  • Current Deferred Revenue was $475680.0 for Q4 2020 at Aytu Biopharma, up from $232576.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $475680.0 in Q4 2020 and troughed at $1450.0 in Q2 2018.
  • The 4-year median for Current Deferred Revenue is $13990.0 (2018), against an average of $145070.9.
  • Year-over-year, Current Deferred Revenue surged 397.0% in 2016 and then tumbled 98.43% in 2017.
  • A 4-year view of Current Deferred Revenue shows it stood at $426000.0 in 2016, then tumbled by 98.88% to $4787.0 in 2017, then soared by 192.25% to $13990.0 in 2018, then surged by 3300.14% to $475680.0 in 2020.
  • Per Business Quant, the three most recent readings for AYTU's Current Deferred Revenue are $475680.0 (Q4 2020), $232576.0 (Q3 2020), and $339336.0 (Q2 2020).